About Us

Our team is driven and passionate about developing targeted medicines that change the course of cancer.

  • Leadership
  • Board of Directors
  • Founders
  • Investors

Cedilla is led by a team of experienced drug developers and company builders, who have successfully advanced more than 40 small molecules into clinical development, for a range of difficult-to-treat cancers and other diseases caused by protein dysregulation.

Chris Bowden, M.D.

Chief Medical Officer, Agios

Dr. Bowden joined Agios as chief medical officer in May 2014​.  He has more than ​20 years of experience in clinical drug development, including the approval of several cancer medicines ​with the most recent being TIBSOVO® approvals for IDH1 mutation positive AML in the U.S. Prior to joining Agios, Dr. Bowden was vice president product development oncology, franchise lead Read More »

Eli Casdin, MBA

Founder, CIO Casdin Capital

Eli Casdin founded Casdin Capital in 2011 after nearly ten years spent focused on disruptive technologies and business models in life sciences and healthcare, including authoring the black book, The Dawn of Molecular Medicine. Casdin Capital’s combination of long-term vision and strong industry relationships keep it focused on the big picture yet nimble, while maintaining Read More »

Abbie Celniker, Ph.D.

Partner, Third Rock Ventures

Abbie Celniker brings 30 years of experience in R&D and senior leadership roles. A partner at Third Rock Ventures, she focuses on the formation, development and strategy of portfolio companies. She has served as president and CEO of Eleven Biotherapies and Taligen Therapeutics and as a board member and interim chief executive officer at Goldfinch Read More »

Neil Exter, MBA

Partner, Third Rock Ventures

Neil Exter brings more than two decades of experience in biotech business development and strategy. A partner at Third Rock Ventures, he has served in key leadership roles at more than a dozen portfolio companies, including Bluebird Bio, Goldfinch Bio and Revolution Medicines. Before joining Third Rock in 2007, Neil was chief business officer of Read More »

Alexandra Glucksmann, Ph.D.

President and Chief Executive Officer

Sandra Glucksmann is a veteran biopharma executive and experienced scientist who most recently served as founder and chief operating officer of the gene editing company Editas Medicine, Inc. She previously served as senior vice president of research and development at Cerulean Pharma, which she also joined at its founding. Sandra was a founding scientist at Read More »

Rosana Kapeller, M.D., Ph.D.

CEO and President, ROME Therapeutics

Rosana Kapeller is the co-founder, CEO and president of ROME Therapeutics and a fellow at GV (formerly Google Ventures), focused on the intersection of therapeutics and machine learning. In her former role as the founding CSO at Nimbus Therapeutics, Rosana led the company’s drive to apply advanced computational technologies to the design and development of novel therapeutics. In Read More »

Dominik Naczynski, PhD

Senior Vice President, Boxer Capital

Dominik Naczynski, Ph.D., joined Boxer Capital, LLC in 2014. As Senior Vice President, Dr. Naczynski is responsible for conducting due diligence of public and private investments in healthcare. In his role, he also serves as a Member of the Board of Directors for Cedilla Therapeutics, Inc. Dr. Naczynski received a Bachelor of Science degree in Read More »

Jake Simson

Partner, RA Capital Management

Jake Simson is a Partner at RA Capital Management. Jake works on both public and private investments and serves as a Board Director for Xenikos, B.V, Janux Therapeutics, Tyra Biosciences, AavantiBio, and DiCE Molecules. Previously, Jake covered solid tumor oncology landscapes. Jake holds a B.S. in materials science and engineering from MIT and a Ph.D. Read More »

Cedilla was founded by a world-class group of scientists and oncologists, each with expertise that complements specific capabilities within our novel drug discovery approach and driven by the desire to bring innovative medicines to patients.

Alan D’Andrea, M.D.

Alan D’Andrea brings years of research insights into DNA repair pathways, oncoproteins and ubiquitin to Cedilla. A professor of radiation oncology at Harvard Medical School, Alan also serves as director of the Center for DNA Damage and Repair at Dana-Farber Cancer Institute. Alan’s research centers on the molecular signaling pathways that regulate the cellular response Read More »

Steve Gygi, Ph.D.

Steve Gygi brings a deep expertise in mass spectrometry and proteomics, with a particular focus on detecting and quantifying the changes that ensue after a protein is perturbed by an external event, such as pharmacological or pathological intervention. A professor of cell biology at Harvard Medical School, Steve specializes in developing technologies for rapid, sensitive Read More »

Matthew Jacobson, Ph.D.

Matt Jacobson is a veteran researcher and entrepreneur with deep experience in both molecular biophysics and drug discovery. A professor at the University of California, San Francisco School of Pharmacy, Matt focuses on research including predicting protein function and regulation, creating new methods for computer-aided drug design and investigating new approaches to treating neurodegenerative diseases. Read More »

William Kaelin, Jr., M.D.

Bill Kaelin’s distinguished research career has focused on the proteins encoded by tumor suppressor genes and how mutations in those genes cause cancer. His work on the VHL protein delivered new insights into how cells respond to changes in oxygen levels – and motivated the successful clinical testing of VEGF inhibitors, which are now approved Read More »

Jack Taunton, Ph.D.

Jack Taunton has spent much of his career developing biochemical tools to illuminate cellular processes relevant to cancer and autoimmune diseases. His work designing covalent inhibitors that target protein kinases led to a drug candidate that’s now advancing through clinical trials. He also discovered a family of cyclic depsipeptides that represent a promising new class Read More »

RA Capital logo
Janus Henderson Investors logo